Ocular Therapeutix, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 267
- Market Cap
- -
- Website
- http://www.ocutx.com
Clinical Trials
31
Trial Phases
5 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (28 trials with phase data)• Click on a phase to view related trials
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Ocular Therapeutix, Inc.
- Target Recruit Count
- 825
- Registration Number
- NCT06495918
- Locations
- 🇺🇸
Associated Retina Consultant, Gilbert, Arizona, United States
🇺🇸Associated Retina Consultants, Ltd., Phoenix, Arizona, United States
🇺🇸Retinal Research Institute, LLC, Phoenix, Arizona, United States
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- Drug: OTX-TKI (axitinib implant)
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Ocular Therapeutix, Inc.
- Target Recruit Count
- 344
- Registration Number
- NCT06223958
- Locations
- 🇺🇸
Retina Associates of Cleveland, Inc. - Beachwood, Beachwood, Ohio, United States
🇺🇸SC CNI Retina Consultants of Charleston, Beaufort, South Carolina, United States
🇺🇸Associated Retina Consultants - Gilbert, Gilbert, Arizona, United States
OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)
- Conditions
- Eye DiseasesDry Eye Syndromes
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Ocular Therapeutix, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05814757
- Locations
- 🇺🇸
Ocular Therapeutix, Memphis, Tennessee, United States
Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
- Conditions
- Non-proliferative Diabetic Retinopathy
- Interventions
- Drug: Sham
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Ocular Therapeutix, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT05695417
- Locations
- 🇺🇸
Ocular Therapeutix Inc, Bellaire, Texas, United States
🇺🇸Ocular Therapeutix, Inc., Reno, Nevada, United States
🇺🇸Ocular Therapeutiux, Inc., Austin, Texas, United States
A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)
- Conditions
- Ocular HypertensionOpen Angle Glaucoma
- Interventions
- Drug: OTX-TIC low dose Travoprost Intracameral ImplantDrug: OTX-TIC high dose Travoprost Intracameral Implant
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Ocular Therapeutix, Inc.
- Target Recruit Count
- 83
- Registration Number
- NCT05335122
- Locations
- 🇺🇸
Ocular Therapeutix, Inc., Kenosha, Wisconsin, United States
🇺🇸Ocular Therapeutiux, Inc., Fargo, North Dakota, United States
🇺🇸Ocular Therapeutix Inc, Oklahoma City, Oklahoma, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next